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Epigenetics: Dissecting Gene 
Expression Alteration in PDAC
Alia Abukiwan and Martin R. Berger
Abstract
Pancreatic cancer is the fourth leading cause of cancer deaths, with a low 
5-year survival rate of about 7% due to its highly invasive nature. Pancreatic ductal 
adenocarcinoma (PDAC) comprises more than 90% of all pancreatic cancer cases. 
At the time of detection, around 80% of cases harbor metastases due to the lack 
of early diagnosis. For decades, scientists have primarily focused on dissecting the 
origin of pancreatic cancer through genetic alterations and their contribution to 
diagnosis. Recently, PDAC research has turned into epigenetics to revolutionize our 
understanding about the silencing of critical regulatory genes. Epigenetic events can 
be divided mechanistically into various components, including DNA methylation, 
histone posttranslational modification, nucleosome remodeling, and regulation of 
transcription or translation by microRNA. The identified epigenetic processes in 
PDAC contribute to its specific epigenotype and are correlated phenotypic features. 
Strikingly, some of them have been suggested to have potential as cancer biomarkers, 
for disease monitoring, prognosis, and risk validation. As epigenetic aberrations are 
reversible, their correction will become as a promising therapeutic target.
Keywords: PDAC, epigenetics, DNA methylation, histone modification,  
microRNA, 3’ UTR
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) comprises more than 90% of all 
pancreatic cancer cases. It is highly aggressive, extremely lethal and shows resis-
tance to chemotherapy [1–3]. At diagnosis, around 80% of PDAC cases have already 
metastasized, thus rendering the current therapeutic options practically ineffective. 
In line with this, potentially curative surgical resection is limited to a very small 
portion of patients [4].
On the other hand, cancer metastasis is associated not only with simple gene/
protein expression models but also with the existence of epigenetic mechanisms [5], 
which complicates this process through DNA methylation, histone modifications, 
and microRNA regulation (see Figure 1). Recent studies uncovered the regulatory 
mechanisms of each process and their key role in EMT and cancer metastasis [6].
2. PDAC from genetics to epigenetics
Historically, the development of PDAC was attributed to DNA mutations, which 
are classified into three main types: oncogenes (KRAS, BRAF, AKT2, MYB, and AIBI), 
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tumor suppressor genes (p16, CDKN2A, p53, p21, BRCA2, and SMAD4), and genome 
maintenance and repair genes (MLH, MSH2, and BRCA2) [1, 2]. Several studies 
explained the complexity of genetic aberrations and their regulatory signaling pathways 
[3]. Although a large variety of signal transduction pathways have already been studied 
in PDAC, much less is known about the cross talk between epigenetic mechanism and 
signaling pathways typical for PDAC [1]. Strikingly, there are also particular cases where 
signaling pathways are altered, which directly affect important components of the epi-
genetic machinery. Therefore, a clear understanding of the epigenetic mechanisms and 
their implication in PDAC development will open new avenues of therapy. This approach 
will exploit the intricate process through which cells induce changes at transcription level 
[4–6].
Epigenetic mechanisms are defined in a way that they can both silence or 
activate genes without alteration to the DNA sequence itself. Mechanistically, 
epigenetic changes represent DNA hypermethylation or hypomethylation, histone-
based mechanisms that include posttranslational modifications and nucleosome 
remodeling, as well as aberrant expression of microRNAs [5, 7]. These modifica-
tions affect chromatin structure and promoter accessibility, which contribute to 
genetic alterations [8].
In PDAC, the famous mutant gene KRAS and its downstream signaling cascade 
are an example for the low therapeutic effect, which is accomplished by current 
therapies against this gene and its downstream effectors. Interestingly, recent stud-
ies demonstrate that dysregulation of epigenetic regulators is essential for PDAC 
progression as well as for that of many other tumors [9]. Genomic deletions, muta-
tions, and rearrangements frequently target genes encoding components of the 
chromatin remodeling complex (SWI/SNF), which have been identified in 10–15% 
of PDAC patients [10].
Figure 1. 
Schematic diagram of epigenetic mechanisms influencing gene expression. DNA methylation is an epigenetic 
mechanism through which cytosine residues within CpG regions are covalently modified (left). In addition, 
the modification of histones has two consequences on genes, which pending on the type of modification and 
the target residues can either activate or repress the target gene (middle). The epigenetic mechanism is also 
influenced by microRNAs (miRNAs). These are small noncoding RNAs, which have a proximal length of 
22 nucleotides. Functionally, the miRNAs influence gene expression through base pairing with 3′ UTRs of 
messenger RNAs (right).
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In general, the discovery of the involvement of the epigenetic effect in cancer 
added a new concept of gene therapy and informative markers for the diagnosis 
and prognosis for many malignancies [11]. Whole genomic sequencing studies have 
revealed driver mutations in epigenetic regulators in various cancer types such as 
IDH1/2, DNMT3A, KDM6A, DNMT3B, SMARCB1, and CREBBP/EP300 [12]. In 
PDAC, the sequencing experiments showed more pathogenic mutations in genes 
encoding multiple components of the SWI/SNF complexes, including ARID1A, 
ARID1B, PBRM1, SMARCA2, and SMARCA4 [13]. Additionally, recent studies 
found mutations in important epigenetic regulators like histone methyltransferase 
enzymes MLL1, MLL2, and MLL3 and histone demethylase KDM6A [13, 14]. 
Specifically, KDM6A has been found mutated in 5–10% of PDAC patients [15].
Several studies on familial PDAC have shown an association between DNA 
repair genes’ dysfunction and those genes that are responsible for this inheritance 
(BRCA2, BRCA1, CDKN2A/p16, STK11/LKB1) [13, 16]. Strikingly, the altered 
DNA repair system is a hallmark of cancer, which causes genome instability and 
DNA damage [17]. Each cell contains a specific enzymatic system termed the DNA 
mismatch repair (MMR), which is responsible for detecting and correcting DNA 
replication errors [18, 19]. Loss or silencing of any protein in this system leads to 
the accumulation of gene mutations. In this regard, studies reported that MMR 
inactivation was caused by the epigenetic silencing of the hMLH1 and hMLH2 genes 
[20, 21]. The hMLH1 protein is one component of a family of seven members of 
MMR proteins that work coordinately to regulate DNA replication error in humans 
[20]. In this context, hypermethylation of the hMLH1 promoter has been shown 
to be an early detection marker of esophageal cancer and also a prognostic marker 
in colorectal and pancreatic cancers. On the other hand, this mechanism cannot be 
generalized, as methylation of the hMLH2 gene results less clear into gene inactiva-
tion, because the respective promoter is a weak target for CpG island methylation 
[16, 17, 20–22].
Another example of an affected DNA repair gene is the O6-methylguanine-DNA 
transferase (MGMT), which is most intensively regulated by CpG promoter meth-
ylation [23]. MGMT is responsible for removing alkyl groups from O6 in guanine and 
thus prevents mismatch errors during DNA replication. The silencing of the MGMT 
activity in human colorectal adenomas has been linked to K-ras GC → AT transition 
mutations [24, 25]. Interestingly, the epigenetic silencing of MGMT has two main 
effects in human cancer. First, it reveals a new mutator pathway that causes the 
accumulation of G-to-A transition mutations. Second, there is a strong and signifi-
cant positive association between MGMT promoter hypermethylation and enhanced 
tumor sensitivity to alkylating drugs. These findings highlight the significance of 
MGMT promoter hypermethylation in translational cancer research [17, 26, 27].
3. DNA methylation
The first epigenetic modification to be identified was DNA methylation [28], 
which is based on stable and heritable changes in gene structure without a change in 
DNA sequence [12]. Methylation refers to the addition of a methyl group to the fifth 
carbon in cytosine forming 5-methylcytosine (5-mC), which is mediated by DNMTs 
[29]. Generally, methylation occurs in intergenic regions and repetitive sequences 
such as satellite repeats, and long and short interspersed nuclear elements, while 
CpG islands of gene promoters often are unmethylated [5, 7, 30]. Interestingly, the 
global effects of epigenetic alterations in gene regulatory sequences from over 100 
cancer cell lines have been identified by the ENCODE project [31]. Normally, DNA 
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methylation is critical for maintaining pluripotency, X chromosome inactivation, 
and genome imprinting [12]. Aberrant DNA methylation is one of the hallmarks of 
cancer [32].
Methylation of DNA is catalyzed by the enzymes DNMT3A and DNMT3B and 
is then maintained by the major DNA methyltransferase DNMT1, which is also 
assisted by DNMT3A and DNMT3B [9, 12]. A recent study found that DNMT1, 
DNMT3A, and DNMT3B are themselves differentially methylated in PDAC [33]. 
Besides, a very recent finding suggests that the interactions between TP53 and 
H3K4, MLL3 and MOZ genes play a major role in chromatin regulation [34]. The 
methylation of tumor suppressor genes is the best-characterized epigenetic event 
in several malignancies, including PDAC [11]. In fact, several genes such as APC, 
BRCA1, P16INK4a, P15INK4b, RARβ, and p73 are frequently methylated [10]. 
Recent studies have revealed that apparent DNA methylation occurred in critical 
signaling pathways in PDAC such as TGFβ, WNT, integrin, cell adhesion, and axon 
guidance signaling pathways [35]. Likewise, TGFβ induces epithelial-mesenchymal 
transition (EMT) by enhancing hypermethylation of CpG islands in the VAV1 gene 
promoter [36] (see Figure 2). Furthermore, the WNT signaling pathway is a target 
of hypermethylation in PDAC. This has been found for WNT ligands WNT5A, 
WNT7A, and WNT9A, or the cell surface receptor FZD9, or the cytoplasmic 
transducer APC2, the nuclear factors SOX1, SOX7, SOX14, and SOX17, and the 
pathway inhibitors FRZB, SFRP1, SFRP2, KREMEN2, NKD2, and WIF1. Strikingly, 
the tumor suppressor candidate HIC1 is hypermethylated, which is acting as a 
transcriptional repressor for abnormal survival circuits of the transcription factors 
involved in the WNT signaling pathway [33, 37].
Furthermore, several studies demonstrated that promoter DNA hypermeth-
ylation is associated with the transcriptional repression of multiple microRNAs 
(miRNAs). This results into upregulation of oncogenic target genes of the microR-
NAs, such as observed for the downregulation of miR-181b, which promotes the 
Figure 2. 
Schematic diagram of signaling pathways in PDAC, which are deregulated by DNA methylation. Critical 
tumor suppressors and transcription factors are silenced, whereas oncogenes are activated. This deregulation 
promotes EMT and metastasis.
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Gene Gene name Epigenetic 
alteration
Function References
CADM1 Cell adhesion 
molecule 1
Hypermethylation Cell-cell interaction [41]
CDH1 Epithelial cadherin Hypermethylation Cell adhesion and 
invasion
[42]
DKK3 Dickkopf-related 
protein 3
Hypermethylation Tumor suppressor [43]
S100A4 S100 calcium-
binding protein A4
Hypermethylation Invasion, motility, 
and tubulin 
polymerization
[44]
P16 Cyclin-dependent 
kinase inhibitor 2A
Hypermethylation Multiple tumor 
suppressor
[45]
DNMT3A DNA (cytosine-5-)-
methyltransferase 
3 alpha
Hypermethylation Enzyme [33]
BMP3 Bone morphogenetic 
protein 3
Hypermethylation Growth factor [33]
ST6GAL2 ST6 beta-
galactosamide 
alpha-2,6-
sialyltranferase 2
Hypermethylation Generation of the cell 
surface carbohydrate 
determinants and 
differentiation 
antigens
[42]
ST8SIA5 ST8 alpha-N-acetyl-
neuraminide α-2,8-
sialyltransferase 5
Hypermethylation A member of 
glycosyltransferase 
family
[42]
ST8SIA2 ST8 α-N-acetyl-
neuraminide alpha-
2,8-sialyltransferase 
2
Hypermethylation A member of 
glycosyltransferase 
family
[42]
ST8SIA3 ST8 α-N-acetyl-
neuraminideα-2,8-
sialyltransferase 3
Hypermethylation A member of 
glycosyltransferase 
family
[42]
AKT1 v-Akt murine 
thymoma viral 
oncogene homolog 1
Hypermethylation Kinases [30]
LCN2 Lipocalin 2 Hypomethylation Epithelial 
differentiation
[33]
CCND2 Cyclin D2 Hypermethylation Cell cycle control [33]
CLDN4 Claudin-4 Hypomethylation Cell adhesion [44]
miR-9-1 MicroRNA-9 Hypomethylation miRNA translation 
control
[40]
P59 Cyclin-dependent 
kinase inhibitor 1C
Hypermethylation Cyclin-dependent 
kinase inhibitor
[34]
P16 Cyclin-dependent 
kinase inhibitor 2A
Hypermethylation Cyclin-dependent 
kinase inhibitor
[33]
RARB Retinoic acid 
receptor
Hypermethylation Cell growth control [33]
SFN Stratifin 
(14-3-3sigma)
Hypomethylation P53-induced G2/M 
cell cycle arrest
[9]
LCN2 Tissue factor 
pathway inhibitor
Hypomethylation Epithelial 
differentiation
[9]
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Gene Gene name Epigenetic 
alteration
Function References
CDKN1C/
P57
Cyclin-dependent 
kinase inhibitor 1C
Hypomethylation Cyclin-dependent 
kinase inhibitor
[42]
FOXE1 Forkhead box E1 Hypomethylation Thyroid transcription 
factor
[42]
Table 1. 
A series of methylated genes in PDAC.
expression of BCL 2 [38]. Moreover, downregulation of the miR-29 family was 
associated with the overexpression of the DNA methyltransferases DNMT3A and 
DNM3B [39]. The noncoding RNAs and antisense RNA sequences are strongly 
involved in the respective DNA hypermethylation process, which silences important 
genes such as polycomb group (PcGs), which in turn may expose these regions to 
DNA methylation changes [40]. More examples are listed in Table 1, all of which 
are related to PDAC.
4. Histone modification
Nucleosomes are considered to be the basic constituents of chromatin. Each 
nucleosome is an octamer of histones, which consist of two copies each of histone 
proteins H2A, H2B, H3, and H4 [46]. The most interesting epigenetic events in PDAC 
are histone modifications, since several studies revealed that the most frequently 
mutated epigenetic genes occurred in the histone family [13]. The posttranslational 
modifications include methylation, acetylation, citrullination, phosphorylation, 
SUMOylation, and ADP ribosylation. However, the most studied histone modifica-
tions in cancer are lysine alterations, including lysine methylation, acetylation, and 
phosphorylation [47–49]. In normal cell development, histone modifications regulate 
critical cell processes such as DNA replication and transcription or repair [46], while 
in cancer, histone modifications contribute to the maintenance of malignant pheno-
types. In PDAC, the most common modification includes methylation and acetylation 
of lysine residues within the N terminal tails of histone proteins [11].
In the context of epithelial-mesenchymal transition (EMT) in PDAC, SNAIL is a 
critical transcription repressor of E-cadherin in EMT process. It plays a significant 
role in embryonic development and tumorigenesis [50]. Moreover, SNAIL has an 
essential function in histone modifications. This includes the activation of a set 
of chromatin modifiers such as lysine-specific demethylase, euchromatic histone 
lysine methyltransferase 2 (G 9a), suppressor of variegation 3–9 homolog 1 histone 
methyltransferases (Suv39H1), SIN3 transcription regulator family member A 
(SIN3A), and histone deacetylases (HDAC1 and HDAC2) [51, 52].
4.1 Histone methylation
Methylation of histones is coordinated by histone methyltransferases (HMTs) 
and histone demethylases (HDMs). There are at least 17 different HMTs, all of which 
share the conserved (Su (var) 3–9, enhancer-of-zeste, trithorax) motif. The lysine 
methylation residue is most common and is mediated by histone lysine methyl-
transferases (HKMTs) [53]. Particularly, methylation at H3K9, H3K27, and H3K20 
is associated with transcriptional repression, while methylation of H3K4, H3K36, 
and H3K79 causes transcriptional activation [47]. The silencing of tumor suppressor 
genes in cancer is caused by the corresponding activities of the HMT and HDMT 
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enzymes. On the other hand, the H3K27me3-specific HMT EZH2 (enhancer of zeste 
homolog 2), the catalytic subunit of PRC2, is overexpressed in a broad range of solid 
tumors, including prostate, lung, breast, colon, skin, and pancreatic cancers [54, 55].
The most frequently altered histone methylated genes in PDAC are KDM6A and 
MLL2 [33]. KDM6A is an H3K27me3 demethylase, which has a role in endoderm 
differentiation by regulating the expression of WNT signaling and HOX genes 
[56]. Other studies found that the loss of trimethylation at K27 of histone H3, 
which causes nuclear accumulation of EZH2, is strongly correlated with a poor 
PDAC outcome [57]. Various interactions have been shown to occur between DNA 
methylation and histone methylation. For example, the interaction between EZH2 
and DNMTs renders the EZH2 gene a potential therapeutic target. Mucins (MUCs) 
are also known to play essential roles in tumor growth and invasion in pancreatic 
neoplasms. MUC1 and MUC4 are high-molecular-weight transmembrane mucins. 
Overexpression of mucins in cancer is associated with poor prognosis. It has been 
shown that mucin expression changes in PDAC are due to DNA methylation of H3 at 
the lysine9 residue [58, 59].
4.2 Histone acetylation
Histone acetylation is the first discovered histone modification. The acetylation 
of lysine residues neutralizes their positive charge, which induces chromatin relax-
ation and activates a set of genes associated with transcription. On the other hand, 
removal of the acetyl groups is associated with gene silencing. Histone acetylases 
(HATs) and deacetylases (HDAC) are the required enzymes for this process [60, 61] 
(see Figure 3a).
Figure 3. 
Schematic diagram on the role of HDACs in PDAC. (A) HDACs mediate E-cadherin translational repression 
by activating the binding of EMT transcription factors to the E-boxes present in the E-cadherin promoter.  
(B) SIRT6 mediates the deacetylation of p53, FOXO3A, and C-Myc, which leads to increased metastasis and 
drug resistance.
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Recent studies show a series of significant alterations of the acetylation process 
in PDAC, as well as mutations in the histone acetylase EP300 [33]. Furthermore, 
the SIRT6 gene is associated with the deacetylation of histone H3 at lysine residues 
9 and 56, thus increasing the expression of the SIRT6 gene associated with PDAC 
metastasis by deacetylation of p53 and FOXOA3 [62](see Figure 3b). For instance, 
the activation of KRAS and increased expression of the c-Myc transcription factor 
promote PDAC metastasis [13]. Also, expression of HDAC7 and HDAC2 has been 
found increased in PDAC [63]. In addition, HDACs/HATs play important roles in 
the activation of several tumor suppressor genes in PDAC, such as p53 and EP300 
[11, 14, 53, 64].
A recent study identified the acetylation of glutamate oxaloacetate transaminases 
2 (GOT2) at three lysine residues (K159, K185, and K404) in PDAC. This promotes 
the transfer of NADH from the cytoplasm into mitochondria, enhancing PDAC cell 
proliferation and tumor growth in vivo. On the other hand, the acetylation of GOT2 
at only K159 is correlated with downregulation of SIRT3 expression [65].
4.3 Histone phosphorylation
Histone phosphorylation has been associated with different cell processes, 
including apoptosis, cell cycle, DNA transcription, DNA repair, chromosome 
condensation, gene regulation, cell signaling pathways, energy, and metabolic path-
ways [66]. Phosphorylation of histones occurs on serine, threonine, and tyrosine 
residues, a process mediated by different kinases and phosphatases [46]. In cell 
development, the most important site for histone phosphorylation is the serine 10 
of histone H3 (H3S10P), which is mediated by the Aurora-B kinase. This modifica-
tion is a critical event in cell mitosis and meiosis [67].
Several studies identified histone phosphorylation changes during DNA dam-
age, such as the phosphorylation of serine 139 on the histone H2A(X). On the other 
hand, phosphorylation of serines, e.g., 10 and 28 on H3, and serine 32 on H2B 
have been contributed by the activation of the epidermal growth factor (EGF). 
Moreover, H3ser28p mediated the expression of c-fos and α-globin [68–70].
It has been shown that H2A T120 is phosphorylated in PDAC by VRK1 on the 
promoter region of CCND1, which consequently activates the transcription of cyclin 
D1 [71]. Besides, KRAS is most well-studied and known activated oncogene in PDAC 
[72]. Other studies have implicated the activation of the Ras-MAPK pathway with 
the upregulation of phospho-ERK1/2 and their downstream levels of H3 S10ph [73].
5. MicroRNA
MicroRNAs (miRNAs) are small (20–23 nucleotides), endogenous, noncoding, 
single-stranded RNA molecules, which control the expression of around 60% 
of the protein-coding genes [74]. Moreover, they can control both physiological 
and pathological processes, such as development and cancer [75]. In addition, the 
miRNA machinery is of great importance for drug development, since a func-
tional miRNA machinery is a compulsory prerequisite for any RNA interference 
(RNAi)-based therapy approach. A total of 700 miRNAs have been discovered 
in human diseases, and more than 1000 predicted miRNA genes are yet to be 
experimentally validated [76].
Mature microRNAs require several steps of preprocessing before they can become 
functional. After they are transcribed by RNA polymerase II/III from intragenic 
regions or from regions that code for introns, the primary transcript (pri-miRNA) 
is processed by the ribonuclease Drosha and DGCR8 in the nucleus. The process 
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produces pre-microRNAs, hairpin-shaped intermediates of 70–100 nucleotides. 
Exportin-5, a Ran-GTP-dependent dsRNA-binding protein, transports pre-microR-
NAs into the cytoplasm where they are further processed by the ribonuclease Dicer 
and TRBP (Tar RNA-binding protein) into a double-stranded miRNA. The strands 
separate and a mature single-stranded molecule join an RNA-induced silencing com-
plex (RISC). The double miRNA strands are required to interact with RISC complex 
or to be degraded. Ordinarily, one miRNA strand can give rise to two individual 
mature miRNA sequences with different targets due to complementary seed sequence 
[74, 77, 78]. The single-stranded mature microRNA remains stable on the miRISC and 
induces posttranscriptional silencing of one or more target genes, usually through 
imperfect pairing with a target sequence in the 3’ UTR [74]. However, this is not the 
only binding region for miRNAs, as there are also binding sites located in 5’ UTR or 
even within the coding DNA sequence of mRNAs [77]. The seed sequence or seed 
region is a conserved heptametrical sequence, which is mostly situated at positions 
2–7 from the miRNA 5’ end [79, 80]. Furthermore, degradation of mature miRNAs 
appears to depend on their activity; in the absence of complementary targets, the 
miRNA could be released from miRNA-RISC complex, and then its 5′ end becomes 
accessible to the 5′ → 3′ exonuclease XRN2, which degrades the miRNA [81].
Cancer represents a heterogeneous group of diseases characterized by uncon-
trolled growth of cells, high proliferation rates, and apoptosis resistance. All of 
these features result from a complex of structural and expression abnormalities of 
genes, including those encoding microRNAs [75, 82]. The classification of cancer 
is more accurately defined with microRNA profiling than with mRNA profiling 
because of the strong correlation between microRNA expression signatures and 
tumor origin [75]. In general, microRNAs have two main functions in cancer; they 
can act as tumor suppressors (TSmiRs) or oncogenes (OncomiRs) [75, 76, 82, 83].
One of the first indications that miRNAs serve as tumor suppressors (TSmiRs) 
came from Calin and colleagues when they discovered that miR-15a and miR-16-1 
were deleted or downregulated in about 68% of chronic lymphocytic leukemia 
(CLL) samples. MiR-15a and miR-16-1 have been shown to control the expression 
of VEGF, a key proangiogenic factor involved in tumor angiogenesis. Furthermore, 
both of them induce the apoptosis of leukemic cells by affecting the antiapoptotic 
protein BCL2 [75, 84]. Another prominent TSmiR is the let-7 family, located at a 
chromosomal region, which is usually deleted in human cancers. It has been reported 
as a TSmiR in lung, breast [84], urothelial, and cervical cancers [85]. Recent studies 
found that let-7 was able to regulate the RAS oncogene in lung cancer. In addition, 
let-7 regulates late embryonic development by suppressing a number of genes such as 
c-Myc, RAS, and HAMGA2 [76, 82]. Taken together, reduced expression of TSmiRs 
in cancer releases oncogenic genes and promotes tumor initiation and progression.
In contrast, oncogenic miRNAs (OncomiRs) promote tumorigenesis by 
inhibiting tumor suppressor genes that play roles within other functions, such 
as cell differentiation and apoptosis. The first OncomiR that was discovered is 
the miR-17-92 cluster, which encodes miR-17-5p, miR-17-3p, miR-18a, miR-19a, 
miR-20a, miR19b-1, and miR-92-1. This cluster is located on chromosome 13 and 
is commonly found to be amplified in human B-cell lymphomas, lung cancer, and 
anaplastic thyroid cancer cells [86]. Another oncogenic miRNA, miR-21, has been 
validated in nine solid tumor types (lung, breast, head and neck, prostate, colon, 
pancreas, esophagus, stomach, and brain). Experimental data confirmed that 
miR-21 plays a significant role in cancer cell proliferation, apoptosis, and invasion. 
Accordingly, inhibition of miR-21 induces cell cycle arrest, increased apoptosis, and 
increased chemosensitivity to anticancer agents [87].
The important emerging role of miRNAs in many cancer types, together with 
the fact that they can function as TSmiRs or OncomiRs, supports the potential of 
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miRNAs Expression 
status
Target genes References
Let-7 family Downregulated KRAS, MAPK, c-Myc, STAT3 [94, 104]
miR-181s Upregulated TIMP3, TCL1, TGFBI, TRIM2, SIRT1, Bcl2 [91, 105]
miR-26s Downregulated MMP2, MMP14, cyclin D1, Mcl-1, Bcl2 [91, 106, 107]
miR-125a Upregulated Bcl-w, Bcl2 [108]
miR-192 Downregulated SERPINE1 [109]
miR-148a,b Downregulated DNMT3B, Mtif, CCKBR, BCL2 [90, 91, 110]
miR-200 
family
Downregulated VEGF-A, KRAS, KDR, VEGFR2, ZEB1/2 [100, 111–113]
miR-34a Downregulated Notch1/2, Bcl2, SIRIT, CDK4, VEGF [99, 114–117]
miR-375 Downregulated PDK1 [90]
miR-124 Downregulated ITGB1, Rac1, RocK2, EZH1, Bcl2, CDK6 [91, 101, 118]
miR-217 Downregulated KRAS, SIRIT, c-MYC [119, 120]
miR-21 Upregulated PTEN [121]
miR-132 Upregulated Rb1, SMAD2 [122, 123]
miR-208 Upregulated E-cadherin [106]
miR-196-a Upregulated NFKBIA [124]
miR-100 Upregulated IGFR1 [90]
miR-155 Upregulated TP53INP1 [125]
miR-10b Upregulated TIP30 [91]
Table 2. 
Top frequently deregulated miRNAs in PDAC.
miRNAs as a new class of targets in the development of cancer therapies. Several 
studies have focused on targeting miRNAs as an experimental therapy in vitro or 
in vivo [85]. Notably, to modulate cancer-associated miRNAs in vivo, two main 
approaches were established: first, miRNA replacement therapy, which is based on 
adding the miRNAs missing in cancer cells for restoring their normal functions; 
second, inhibition of oncogenic miRNAs by using single-stranded chemically 
modified anti-miR oligonucleotides [85, 88]. The first successful in vivo experiment 
using anti-miRs in conjunction with locked nucleic acids was successfully applied in 
African green monkeys with hypercholesterolemia. The experiments resulted in the 
successful control of triglyceride and cholesterol levels, together with the manage-
ment of disease manifestations with minimal side effects to herald a new research 
approach that is equally applicable in cancer [89].
PDAC shares many features with other solid tumors. Numerous studies 
have reported the significant roles, which miRNAs play in PDAC progression. 
Furthermore, these studies have also provided important information about cellular 
features, such as growth, invasive, and metastatic behavior that have been modified 
or altered in PDAC as a result of miRNAs, thus highlighting, to a large extent, the 
significance of miRNAs in PDAC progression [90]. High-throughput microarray 
technologies have been used to extensively profile miRNA signatures in cell lines, 
normal frozen tissues, formalin-fixed paraffin-embedded tissues (FFPE), blood, 
and fine needle aspiration biopsy (FNAB) samples, in order to establish a common 
expression pattern in PDAC [91]. Recently, a meta-analysis reviewed 11 miRNA 
profiling studies in PDAC and reported 439 miRNAs as deregulated in the 538 
PDAC samples that were evaluated [92]. This analysis defines a common pool of 
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miRNAs that are atypically expressed in PDAC, and the potential renormaliza-
tion of these miRNAs and/or expression patterns could help create a therapeutic 
approach in managing this aggressive disease [93].
The commonly deregulated miRNAs are associated with major regulatory genes 
in several signaling pathways (Table 2), which are involved in most aspects of cellu-
lar physiology including regulation of cell cycle, differentiation, proliferation, and 
apoptosis. Notably, altered miRNA expression in PDAC contributes to metastasis 
and drug resistance [92, 94, 95]. The more frequently deregulated miRNAs in PDAC 
include miR-21, the expression of which is regulated by KRAS, and correlates with 
the degree of tumor progression [90]. KRAS is an important molecule in PDAC and 
is a direct target of miR-96, miR-217, miR-126, and miR-200c. The overexpression 
of these miRNAs reduces the level of KRAS expression, resulting in decreased cell 
invasion, migration, and tumor growth [96, 97]. Strikingly, two of these miRNAs, 
miR-145 and miR-200c, function as a regulatory network in the AKT-PI3K signaling 
pathway [98]. Conversely, it has been reported that KRAS activation suppresses 
the expression of the miR-134/145 cluster via the Ras responsive element-binding 
protein (RREB1) [99]. The miR-200 family is also frequently deregulated in PDAC 
and plays a significant role in EMT inhibition. One study demonstrated that 
miR-200 negatively regulates ZEB1 and ZEB2, which are both direct repressors of 
E-cadherin [100]. In the context of epigenetic modifications, several studies have 
found TSmiRs in PDAC, including miR-9-1, miR-124s, miR-192, miR-615-5p, and 
miR-1247, which were hypermethylated [44, 101–103].
6. Conclusions
For the high mortality, poor prognosis, and undefined therapeutic targets in 
PDAC, the unraveling of the complex molecular layers driving this lethal cancer 
is a prerequisite for more effective therapeutic strategies and consistent diag-
nostic markers. The recent research on epigenetic mechanisms has significantly 
enriched our knowledge about the regulatory characteristics involved in the 
initiation, progression, and metastasis of PDAC. This book chapter has focused 
on the most critical epigenetics mechanisms, including DNA methylation, histone 
modifications, and modulated expression of miRNAs that play a significant role 
in PDAC tumorigenesis, and could serve as future therapeutic targets. Currently, 
significant emphasis is still given on detecting somatic genetic alterations in 
PDAC. However, it seems also promising to investigate the underlying epigen-
etic mechanisms for completing the full puzzle of altered gene expression in 
PDAC. The epigenetics field has developed strongly and will continue to advance 
into a frontier field for PDAC research. Additionally, it is essential to highlight 
the features of epigenetic mechanisms of gene regulation—their reversibility. 
This feature provides a ground for specifically targeting the epigenetic changes 
contributing to PDAC.
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